Sequential Bioequivalence Trial Designs with Increased Power and Controlled Type I Error Rates

Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 3

Abstract

The online version of this article (doi:10.1208/s12248-013-9475-5) contains supplementary material, which is available to authorized users.

Authors and Affiliations

Anders Fuglsang

Keywords

Related Articles

Hidalgo, I. J., Raub, T. J., and Borchardt, R. T.: Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability, Gastroenterology, 96, 736–749, 1989—The Backstory

This manuscript was written with the knowledge and input of Ismael J. Hidalgo and Thomas J. Raub, who were coauthors of the 1989 Gastroenterology paper describing for the first time Caco-2 cell monolayers as a cell cultu...

Genetic variations in human G protein-coupled receptors: Implications for drug therapy

Numerous genes encode G protein-coupled receptors (GPCRs)-a main molecular target for drug therapy. Estimates indicate that the human genome contains approximately 600 GPCR genes. This article addresses therapeutic impli...

Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update

The human breast cancer resistance protein (BCRP, gene symbol ABCG2) is an ATP-binding cassette (ABC) efflux transporter. It was so named because it was initially cloned from a multidrug-resistant breast cancer cell line...

Polymer-drug conjugates as modulators of cellular apoptosis

The successful clinical application of polymer-protein conjugates (PE Gylated enzymes and cytokines) and the promising results arising from clinical trials with polymerbound chemotherapy (eg, doxorubicin or paclitaxel) h...

Three-dimensional structure of fibrolase, the fibrinolytic enzyme from southern copperhead venom, modeled from the x-ray structure of adamalysin II and atrolysin C

The fibrinolytic enzyme from southern copperhead snake venom, fibrolase, contains 1 mole of zine per mole of protein, belongs to the major family of metalloproteinases known as the metzincins, and has been shown to degra...

Download PDF file
  • EP ID EP681126
  • DOI  10.1208/s12248-013-9475-5
  • Views 50
  • Downloads 0

How To Cite

Anders Fuglsang (2013). Sequential Bioequivalence Trial Designs with Increased Power and Controlled Type I Error Rates. The AAPS Journal, 15(3), -. https://europub.co.uk/articles/-A-681126